Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Key Points

• Revolution Medicines will report Q1 2026 results after the close on Wednesday, May 6 (earnings call 4:30 PM ET); analysts expect EPS of ($1.78) and revenue of about $3.83M.
• Shares jumped 10% to open at $144.83, trading near a 52‑week high ($155.70) with a market capitalization of roughly $28.7B despite a negative trailing PE (−24.51).
• Most analysts rate the stock as Buy/Strong Buy with an average target of $78.94, while insiders sold about $24.5M of stock last quarter and institutional ownership is very high.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) is projected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Revolution Medicines to post earnings of ($1.78) per share and revenue of $3.8290 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same period in the prior year, the firm earned ($1.12) earnings per share. On average, analysts expect Revolution Medicines to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Revolution Medicines Stock Up 10.0%

RVMD opened at $144.83 on Wednesday. Revolution Medicines has a fifty-two week low of $34.00 and a fifty-two week high of $155.70. The business has a 50-day moving average of $109.16 and a 200-day moving average of $91.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The company has a market capitalization of $28.70 billion, a PE ratio of -24.51 and a beta of 1.01.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group assumed coverage on Revolution Medicines in a research note on Monday, March 16th. They set a "buy" rating for the company. Truist Financial raised Revolution Medicines to a "strong-buy" rating in a research note on Monday. UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They set a "buy" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a research note on Tuesday, April 21st. Finally, HC Wainwright reissued a "buy" rating on shares of Revolution Medicines in a research note on Wednesday, April 22nd. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $78.94.

Insider Buying and Selling

In other Revolution Medicines news, insider Lin Wei sold 2,073 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $206,222.04. Following the transaction, the insider directly owned 101,366 shares of the company's stock, valued at $10,083,889.68. The trade was a 2.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Margaret A. Horn sold 4,583 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the transaction, the chief operating officer directly owned 157,570 shares in the company, valued at approximately $15,675,063.60. This represents a 2.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 184,592 shares of company stock worth $24,499,532. 8.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. grew its holdings in shares of Revolution Medicines by 197.1% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,205,555 shares of the company's stock worth $175,672,000 after purchasing an additional 1,463,155 shares in the last quarter. Nextech Invest Ltd. grew its holdings in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Revolution Medicines during the 2nd quarter worth approximately $44,148,000. Bellevue Group AG grew its holdings in shares of Revolution Medicines by 21.7% during the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company's stock worth $260,298,000 after purchasing an additional 994,538 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its holdings in shares of Revolution Medicines by 200.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock worth $95,580,000 after purchasing an additional 800,000 shares in the last quarter. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.